Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: A multi-institutional analysis of 941 cases

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Lin, Ning ^a   Yan, Wei ^a   Gao, Kaiming ^a   Wang, Yinyi ^a   Zhang, Junxia ^a   You, Yongping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CLASSICAL GLIOBLASTOMA; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; EGFR GENE; GENE EXPRESSION; GENE IDENTIFICATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MESENCHYMAL GLIOBLASTOMA; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MULTICENTER STUDY; NEURAL GLIOBLASTOMA; OLIGODENDROGLIOMA; ONCOGENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PREVALENCE; PRONEURAL GLIOBLASTOMA; TUMOR CLASSIFICATION; BRAIN NEOPLASMS; CLASSIFICATION; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL; WORLD HEALTH ORGANIZATION;

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

BRAIN NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; NEOPLASM GRADING; PREVALENCE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 84899675054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094871     Document Type: Article

References (12)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710. (Pubitemid 350070717)
2. Yan W, Zhang W, Jiang T (2011) Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res 30: 58.
3. Drappatz J, Norden AD, Wen PY (2009) Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9: 519-534.
4. Wang Y, Jiang T (2013) Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 331: 139-146.
5. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, et al. (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: 9065-9072.
6. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
7. Yan W, Zhang W, You G, Zhang J, Han L, et al. (2012) Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol 14: 1432-1440.
8. Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA, et al. (2009) Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 7: 157-167.
9. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572. (Pubitemid 34526173)
10. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC (1995) Histopathology, classification, and grading of gliomas. Glia 15: 211-221.
11. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173. (Pubitemid 43357943)
12. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, et al. (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69: 2091-2099.